<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Cell Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">J. Mol. Cell. Cardiol</journal-id><journal-title-group><journal-title>Journal of Molecular and Cellular Cardiology</journal-title></journal-title-group><issn pub-type="ppub">0022-2828</issn><issn pub-type="epub">1095-8584</issn><publisher><publisher-name>The Authors. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7191280</article-id><article-id pub-id-type="publisher-id">S0022-2828(20)30121-8</article-id><article-id pub-id-type="doi">10.1016/j.yjmcc.2020.04.031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Gro&#x000df;</surname><given-names>Sonja</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Jahn</surname><given-names>Christopher</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Cushman</surname><given-names>Sarah</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>B&#x000e4;r</surname><given-names>Christian</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0025"><name><surname>Thum</surname><given-names>Thomas</given-names></name><email>thum.thomas@mh-hannover.de</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af0005"><label>a</label>Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany</aff><aff id="af0010"><label>b</label>REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Germany. <email>thum.thomas@mh-hannover.de</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2020</year></pub-date><volume>144</volume><fpage>47</fpage><lpage>53</lpage><history><date date-type="received"><day>9</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>21</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>The current COVID-19 pandemic started several months ago and is still exponentially growing in most parts of the world &#x02013; this is the most recent and alarming update. COVID-19 requires the collaboration of nearly 200 countries to curb the spread of SARS-CoV-2 while gaining time to explore and improve treatment options especially for cardiovascular disease (CVD) and immunocompromised patients, who appear to be at high-risk to die from cardiopulmonary failure. Currently unanswered questions are why elderly people, particularly those with pre-existing comorbidities seem to exhibit higher mortality rates after SARS-CoV-2 infection and whether intensive care becomes indispensable for these patients to prevent multi-organ failure and sudden death. To face these challenges, we here summarize the molecular insights into viral infection mechanisms and implications for cardiovascular disease. Since the infection starts in the upper respiratory system, first flu-like symptoms develop that spread throughout the body. The wide range of affected organs is presumably based on the common expression of the major SARS-CoV-2 entry-receptor angiotensin-converting enzyme 2 (ACE2). Physiologically, ACE2 degrades angiotensin II, the master regulator of the renin-angiotensin-aldosterone system (RAAS), thereby converting it into vasodilatory molecules, which have well-documented cardio-protective effects. Thus, RAAS inhibitors, which may increase the expression levels of ACE2, are commonly used for the treatment of hypertension and CVD. This, and the fact that SARS-CoV-2 hijacks ACE2 for cell-entry, have spurred controversial discussions on the role of ACE2 in COVID-19 patients. In this review, we highlight the state-of-the-art knowledge on SARS-CoV-2-dependent mechanisms and the potential interaction with ACE2 expression and cell surface localization. We aim to provide a list of potential treatment options and a better understanding of why CVD is a high risk factor for COVID-19 susceptibility and further discuss the acute as well as long-term cardiac consequences.</p></abstract><abstract abstract-type="graphical" id="ab0010"><title>Graphical abstract</title><p><fig id="f0010" position="anchor"><alt-text id="al0015">Unlabelled Image</alt-text><graphic xlink:href="ga1_lrg"/></fig></p></abstract><abstract abstract-type="author-highlights" id="ab0015"><title>Highlights</title><p><list list-type="simple" id="l0110"><list-item id="li0230"><label>&#x02022;</label><p id="p0230">COVID-19 patients with underlying CVD have drastically increased risks of mortality.</p></list-item><list-item id="li0235"><label>&#x02022;</label><p id="p0235">SARS-CoV2 uses ACE2 as cell entry receptor.</p></list-item><list-item id="li0240"><label>&#x02022;</label><p id="p0240">Current and novel COVID-19 drugs may act on the SARS-CoV-2 receptor ACE2.</p></list-item><list-item id="li0245"><label>&#x02022;</label><p id="p0245">ACE-I and ARB may interfere with COVID-19 susceptibility and effects on the heart.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>ACE2</kwd><kwd>Cardiovascular disease</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0250">Since the coronavirus disease (COVID-19) is still an emerging pandemic with more than 2.1 million confirmed cases worldwide [<xref rid="bb0005" ref-type="bibr">1</xref>], special focus is currently directed towards the understanding of why people are hospitalized, receive intensive care, and frequently die as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Mortality rates seem particularly high when patients suffer from distinct comorbidities. First studies were initiated mainly on Chinese cohorts, as China is the suspected point of origin of COVID-19. These studies indicate that patients subjected to intensive care units (ICU) frequently show hypertension, diabetes and/or cardiovascular diseases (CVD) [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0015" ref-type="bibr">3</xref>]. These patients demonstrate much higher mortality rates compared with patients that are free of these comorbidities [<xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>]. While higher mortality rates among CVD patients are also associated with other respiratory diseases (especially influenza virus-induced flu or previous SARS epidemics), the question was put forward, whether people treated for heart-related illness are more prone to SARS-CoV-2 viral infection, based on first epidemiological evidence, but particularly based on the presumed upregulation of the SARS-CoV-2 entry receptor. While this association is currently heavily discussed, and will be also be a subject of this review, latest epidemiological studies coming from Europe at least underpin the greater risk for a critical disease progression in this group of patients [<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0045" ref-type="bibr">9</xref>]. Therefore, we here aim to outline the mechanisms influencing the cardiac system because of its central implications in the COVID-19 course. We further highlight currently investigated and upcoming therapy options for COVID-19 patients with cardiac disease conditions.</p><sec id="s0010"><label>1.1</label><title>COVID-19 pandemic, what do we know so far?</title><p id="p0255">The emerging pandemic, originating from a <bold>CO</bold>rona<bold>VI</bold>rus <bold>D</bold>isease outbreak at the end of 20<bold>19</bold> (COVID-19), is based on a positive-sense single-stranded RNA virus probably originating from bats and/or pangolins [<xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>]. The first local outbreak was reported in Wuhan, a small but heavily populated region in China, subsequently spreading rapidly around the world within three months [<xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>]. While the proposed incubation period can last over two weeks, symptoms might already occur five to six days after a COVID-19 infection [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0065" ref-type="bibr">13</xref>]. A substantial number of asymptomatic courses have been reported. To properly address the prevalence, transmission, hospitalization and mortality rates of SARS-CoV-2, it will be of utmost importance to determine the number of asymptomatic cases (including those who are currently infected and recovered). Accordingly, several cross-sectional studies were already launched to determine the presence of anti-SARS-CoV-2 antibodies. Preliminary results from the Heinsberg-Study (named after a town that was the first COVID-19 hotspot in Germany) suggest that around 15% of 500 people chosen at random showed an antibody response [<xref rid="bb0070" ref-type="bibr">14</xref>]. In symptomatic cases, flu-like symptoms range from fatigue, coughing and shortness of breath, to fever as well as gastrointestinal disorders. Less common symptoms are upper respiratory-related signs such as sneezing and a sore throat [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0075" ref-type="bibr">15</xref>,<xref rid="bb0080" ref-type="bibr">16</xref>]. When the symptoms first appear, a relatively rapid spread of the virus towards the lungs might cause severe pneumonia, which then frequently requires an oxygen supply or mechanical ventilation [<xref rid="bb0085" ref-type="bibr">17</xref>]. The progression of a COVID-19 infection towards this critical phase should be urgently avoided if possible, because at this stage there is not only serious damage to the lungs but to the heart due to pre-existing CVDs making COVID-19 a life-threatening infection. In the past two months, unjustified attempts were made to place the number of cases and estimated mortality rates of COVID-19 into perspective by comparing it to influenza [<xref rid="bb0090" ref-type="bibr">18</xref>,<xref rid="bb0095" ref-type="bibr">19</xref>]. The major differences revoking such comparison are: firstly, a suspected high prevalence for asymptomatic disease spreaders; secondly, a prolonged incubation period compared to common seasonal influenza viruses; and thirdly, an extended disease progression, reflected by an average ICU stay of 15&#x0202f;days with a minimum of 10&#x0202f;days in Italy [<xref rid="bb0065" ref-type="bibr">13</xref>,<xref rid="bb0100" ref-type="bibr">20</xref>]. Altogether, this establishes the basis for the COVID-19 outbreak and the fast spread of this pandemic.</p><p id="p0260">A critical disease progression of SARS-CoV-2 infected patients is supposed to be initiated by the inability of the immune system to prevent the spreading of viruses to the lungs. This can rapidly lead to pneumonia evidenced by typical visible features in computed tomographic analyses [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0110" ref-type="bibr">22</xref>]. Delayed clinical treatment of those critical patients causes not only an undersupply of oxygen in the lungs, but additionally causes cardiac ischemia [<xref rid="bb0115" ref-type="bibr">23</xref>,<xref rid="bb0120" ref-type="bibr">24</xref>]. Lung and heart damage is further promoted by an over-reaction of the immune system associated with a pronounced cytokine storm [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>]. Clinical features include extremely elevated levels of interleukin 6 (IL-6) and ferritin [<xref rid="bb0015" ref-type="bibr">3</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>,<xref rid="bb0130" ref-type="bibr">26</xref>], which are also well-known markers for sepsis. The latest guidelines therefore recommend first measuring basic blood parameters in order to assess the state of infection and adjust medication accordingly, even if SARS-CoV-2 infection has not yet been confirmed [<xref rid="bb0135" ref-type="bibr">27</xref>,<xref rid="bb0140" ref-type="bibr">28</xref>]. This can accelerates the treatment, which might then limit critical manifestations.</p></sec><sec id="s0015"><label>1.2</label><title>CVD as a risk factor for COVID-19</title><p id="p0265">The involvement of the cardiovascular system in severe COVID-19 courses is already undisputed, but the specific underlying mechanisms remain to be explored. One proposed mode of action is related to a direct infection of cardiomyocytes (CMCs) by SARS-CoV-2 during the critical phase that leads to the development of myocarditis [<xref rid="bb0145" ref-type="bibr">29</xref>,<xref rid="bb0150" ref-type="bibr">30</xref>]. To date, there is no indisputable evidence for myocarditis in deceased COVID-19 patients, which requires confirmation through a biopsy or an autopsy. Therefore, to address whether inflammation of the cardiac muscle contributes to the observed heart failure (HF), additional investigations are still necessary. A second assumption that is currently pursued, is that an over-activated immune system is predominantly contributing to SARS-CoV-2-induced heart damage. Subsequent to cardiac ischemia as a consequence of pneumonia and the associated acute respiratory distress syndrome (ARDS) [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0155" ref-type="bibr">31</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>], CMC damage and death induces a variety of pro-inflammatory mechanisms, which in turn spiral out of control and further promote loss of CMCs [<xref rid="bb0165" ref-type="bibr">33</xref>]. Hence, a secondary induced cardiac injury seems to be quite likely, although specific evidence is still lacking owing to the currently tense clinical situation. However, these ideas are strongly endorsed by previous studies investigating the SARS-CoV outbreak in 2002 or later on the MERS-CoV-associated epidemic in 2012 [<xref rid="bb0170" ref-type="bibr">34</xref>,<xref rid="bb0175" ref-type="bibr">35</xref>], where acute myocarditis and heart failure have also been reported [<xref rid="bb0180" ref-type="bibr">36</xref>]. Similar long-term implications on the cardiovascular system as observed in a study for SARS-CoV can only be suggested [<xref rid="bb0185" ref-type="bibr">37</xref>].</p><p id="p0270">Considering the multiple effects on the heart, it can already be assumed that previous CVDs would lead to an unfavorable progression of COVID-19. Interestingly, the drastically increased mortality rate in patients with pre-existing or new cardiac injuries is associated with elevated serum levels of troponin T (TnT), a biomarker for cardiac damage. Indeed, the study of Guo et al. points out that CVD patients without significantly raised TnT serum levels only represent a slightly increased mortality compared to patients without CVD [<xref rid="bb0115" ref-type="bibr">23</xref>,<xref rid="bb0190" ref-type="bibr">38</xref>]. Therefore, in the case of expected cardiac damage due to distinct comorbidities or severe disease progression, TnT levels should always be strictly monitored, but also critically interpreted since some medications and interventions themselves can cause an upregulation of TnT [<xref rid="bb0195" ref-type="bibr">[39]</xref>, <xref rid="bb0200" ref-type="bibr">[40]</xref>, <xref rid="bb0205" ref-type="bibr">[41]</xref>]. Together with other biomarkers such as the inflammatory cytokines IL-6 and Ferritin as well as D-dimers [<xref rid="bb0130" ref-type="bibr">26</xref>,<xref rid="bb0165" ref-type="bibr">33</xref>,<xref rid="bb0210" ref-type="bibr">42</xref>,<xref rid="bb0215" ref-type="bibr">43</xref>], TnT may be used to predict the outcome of the SARS-CoV-2 infection and aid in clinical decision making for the best possible treatment options, which ultimately help to reduce COVID-19 mortality [<xref rid="bb0220" ref-type="bibr">44</xref>,<xref rid="bb0225" ref-type="bibr">45</xref>].</p></sec><sec id="s0020"><label>1.3</label><title>COVID-19 and the renin-angiotensin-aldosterone system</title><p id="p0275">The most prevalent comorbidities include hypertension, diabetes, cardiovascular but also pulmonary dysfunctions, cancer, nephrological disorders and cerebrovascular diseases [<xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>, <xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>,<xref rid="bb0045" ref-type="bibr">9</xref>,<xref rid="bb0230" ref-type="bibr">46</xref>]. Published statistics vary between different countries, mainly because of small cohorts, different prevalence of these diseases and inadequate testing of potentially SARS-CoV-2 infected patients. In general, various organ systems are believed to participate in COVID-19 due to the widespread expression of the primary SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2) [<xref rid="bb0235" ref-type="bibr">47</xref>]. ACE2 is an important regulator of the renin-angiotensin-aldosterone system (RAAS), which systemically influences the vasculature and blood pressure via distinct hormones. This endocrine system additionally regulates the fluid and electrolyte balance in the kidneys. Briefly, the peptide prorenin is cleaved in the kidneys and activated renin is then released into the blood stream where it in turn activates angiotensinogen, which is converted into angiotensin I and finally into angiotensin II (AngII). Specific angiotensin-converting enzymes (ACEs), mainly expressed on renal and pulmonary epithelium, facilitate this activation cascade. The vasoconstrictive angiotensin II is the major driver of the blood pressure-increasing response, when the juxtaglomerular apparatus in the kidneys detects critically low blood pressure [<xref rid="bb0240" ref-type="bibr">48</xref>]. Thus, dysregulation of this fine-tuned system results in hypertension and heart failure as well as chronic kidney disease [<xref rid="bb0245" ref-type="bibr">49</xref>,<xref rid="bb0250" ref-type="bibr">50</xref>]. Specific ACE inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) are the first choice as an antihypertensive drug [<xref rid="bb0245" ref-type="bibr">49</xref>,<xref rid="bb0255" ref-type="bibr">51</xref>]. However, ACE2 is a well-characterized negative regulator of the RAAS system as it converts AngII into the vasodilatory fragment Ang 1&#x02013;7, which simultaneously decreases the AngII concentration to further facilitate the antihypertensive effect [<xref rid="bb0260" ref-type="bibr">52</xref>,<xref rid="bb0265" ref-type="bibr">53</xref>]. ACE2 is located on the cell surface e.g. in the renal, cardiac, pulmonary and gastrointestinal systems [<xref rid="bb0270" ref-type="bibr">54</xref>], providing an explanation for the observed symptoms of COVID-19. In the following part of this review, we will highlight potentially connective mechanisms of SARS-CoV-2 and the dysregulated presentation of ACE2 with the described clinical features in the context of cardiac injury.</p></sec><sec id="s0025"><label>1.4</label><title>The role of ACE2 in COVID-19</title><p id="p0280">The central role of ACE2 in cardiac physiology and pathology, as well as the fact that it acts as the major entry receptor for both SARS-CoV and SARS-CoV-2 suggests that it is a promising therapeutic target [<xref rid="bb0235" ref-type="bibr">47</xref>,<xref rid="bb0275" ref-type="bibr">55</xref>]. Receptor binding is facilitated through the viral spike protein that is processed by the protease TMPRSS2 [<xref rid="bb0235" ref-type="bibr">47</xref>]. Then, the spike protein interacts with the extracellular domain of ACE2, which triggers clathrin-dependent endocytosis of the complex [<xref rid="bb0235" ref-type="bibr">47</xref>,<xref rid="bb0275" ref-type="bibr">55</xref>,<xref rid="bb0280" ref-type="bibr">56</xref>]. Interestingly, this interaction is remarkably enhanced in patients suffering from hypertension or coronary heart disease as well as in diabetic or other comorbid conditions [<xref rid="bb0285" ref-type="bibr">[57]</xref>, <xref rid="bb0290" ref-type="bibr">[58]</xref>, <xref rid="bb0295" ref-type="bibr">[59]</xref>]. While elevated plasmin or plasminogen levels have already been associated with patients suffering from these medical conditions, the impact of these increased levels on viral infections was only very recently highlighted by Ji et al. [<xref rid="bb0300" ref-type="bibr">60</xref>]. The viral spike protein is cleaved at a furin site, which is not present in SARS-CoV, by the furin protease plasmin, thereby increasing the cellular uptake of viral particles and enhancing its pathogenicity [<xref rid="bb0280" ref-type="bibr">56</xref>,<xref rid="bb0300" ref-type="bibr">60</xref>]. Furthermore, there is an association of elevated plasmin levels with the strong induction of D-dimer as a product of hyper-fibrinolysis, which is an additional critical parameter of severe COVID-19 progression [<xref rid="bb0210" ref-type="bibr">42</xref>,<xref rid="bb0215" ref-type="bibr">43</xref>,<xref rid="bb0305" ref-type="bibr">61</xref>].</p><p id="p0285">Once the virus enters the cell, the viral RNA is released and the host-cell's cellular programs are utilized for viral replication. In addition to producing infectious progeny, several mechanisms of the SARS-CoV-2 infection and replication influence ACE2 expression and presentation. Firstly, internalization of the receptor is accompanied by a reduced availability on the cell surface. Secondly, so far unknown viral mediators inhibit <italic>ACE2</italic> and concurrently induce <italic>ADAM metallopeptidase domain 17</italic> (<italic>ADAM-17</italic>) gene expression [<xref rid="bb0265" ref-type="bibr">53</xref>,<xref rid="bb0310" ref-type="bibr">62</xref>]. The membrane-bound metalloprotease is involved in processing the tumor necrosis factor &#x003b1; (TNF&#x003b1;), but is also functioning as a &#x0201c;sheddase&#x0201d; by releasing anchored receptors and cytokines [<xref rid="bb0315" ref-type="bibr">63</xref>]. As a physiological regulator of the RAAS system, ADAM-17 mediates cleavage of ACE2, pointing towards its direct involvement in COVID-19 [<xref rid="bb0265" ref-type="bibr">53</xref>]. Thirdly, not only the release of TNF&#x003b1; [<xref rid="bb0315" ref-type="bibr">63</xref>], but also processing of different important pro-inflammatory cytokines such as interleukin 4 (IL-4) and interferon &#x003b3; (IFN&#x003b3;) is accomplished [<xref rid="bb0310" ref-type="bibr">62</xref>,<xref rid="bb0320" ref-type="bibr">64</xref>,<xref rid="bb0325" ref-type="bibr">65</xref>]. The latter two act directly on <italic>ACE2</italic> expression via autocrine pathways [<xref rid="bb0325" ref-type="bibr">65</xref>], further promoting the downregulation of ACE2 on the cellular surface of infected cells, and might secondary imply an imbalance of T cell responses and over-reaction of the immune system by provoking a cytokine storm (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
).<fig id="f0005"><label>Fig. 1</label><caption><p>Overview about the role of ACE-2 during SARS CoV-2 infection.</p><p>Angiotensin II can either bind to the angiotensin II receptor type I (AT<sub>1</sub>-R), where it induces vasoconstriction via the phospholipase C (PLC), proteinkinase C (PKC) pathway, or be processed by angiotensin converting enzyme 2 (ACE2) to generate angiotensin 1&#x02013;7. Afterwards, angiotensin 1&#x02013;7 can bind to the MAS-receptor (Mas-R), which induces a signaling cascade subsequently leading to a vasodilatory effect. During SARS CoV-2 infection, viral spike protein (S) on the surface of the virus binds to ACE2. After processing of the S-protein by the endogenous transmembrane serine protease 2 (TMPRSS2), the viral particle is endocytosed and acidification of the endosome leads to viral and cellular membrane fusion and release of viral single-stranded RNA (ssRNA) into the cytosol. There, the ssRNA is replicated and translated into viral proteins (N, M, E and S). Additional viral mechanisms facilitate the downregulation of endogenous <italic>ACE2</italic> and upregulation of <italic>ADAM metallopeptidase domain 17</italic> (<italic>ADAM-17</italic>) expression. After vesicular transport to the cell surface, ADAM-17 facilitates its role as a &#x0201c;sheddase&#x0201d; and cleaves the extracellular domain of ACE2. Moreover, increased extracellular cytokine concentrations (TNF&#x003b1;, IFN&#x003b3;, IL-4) lead to the activation of cellular proinflammatory pathways by different cytokine receptors. These pathways further support virus-induced downregulation of ACE2 and upregulation of ADAM-17.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="s0030"><label>1.5</label><title>ACE2 as clinical target in the treatment of COVID-19</title><p id="p0290">The consequences of SARS-CoV-2 infection alone are already an enormous stress for the body. Considering that many patients suffer from pre-existing illness and elderly people present a compromised immune system [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0015" ref-type="bibr">3</xref>,<xref rid="bb0330" ref-type="bibr">66</xref>], the severity and the potential life-threat of a SARS-CoV-2 infection becomes very clear. The treatment plan of CVD patients regularly includes inhibitors of the RAAS, namely ACE-I and ARBs. Recently, upregulation of ACE2 has been associated with RAAS inhibitor medication [<xref rid="bb0335" ref-type="bibr">[67]</xref>, <xref rid="bb0340" ref-type="bibr">[68]</xref>, <xref rid="bb0345" ref-type="bibr">[69]</xref>]. The point was recently raised that the susceptibility in those patients is even increased based on high viral loads that were detected in patients with poor outcomes [<xref rid="bb0150" ref-type="bibr">30</xref>,<xref rid="bb0350" ref-type="bibr">70</xref>]. A broad spectrum of institutions and scientist have discussed this topic extensively as treatment guidelines were and are still required very urgently because of the rapidly growing number of cases. Summarizing the most important aspects of this ongoing discussion, antihypertensive drugs should not be discontinued if there is no medical necessity, as uncontrolled blood pressure or clinical instability is a superior high-risk factor for severe complications [<xref rid="bb0355" ref-type="bibr">71</xref>]. So far, there is no evidence of increased susceptibility of hypertensive patients; on the contrary, studies in Chinese cohorts suggest an even lower estimated prevalence of COVID-19 in blood-pressure controlled subjects compared to the distribution of high blood pressure in the population in general [<xref rid="bb0155" ref-type="bibr">31</xref>,<xref rid="bb0230" ref-type="bibr">46</xref>]. Indeed, a retrospective study of hospitalized COVID-19 patients with hypertension identified a lower risk of all-cause mortality in patients under ACE-I and ARB treatment [<xref rid="bb0360" ref-type="bibr">72</xref>]. Moreover, a cardio-protective activity of ACE2 has been previously described in different animal models and clinical studies of heart diseases [<xref rid="bb0365" ref-type="bibr">[73]</xref>, <xref rid="bb0370" ref-type="bibr">[74]</xref>, <xref rid="bb0375" ref-type="bibr">[75]</xref>], concluding that an even desirable effect might be achieved through this medication. Therefore, a clinical trial was initiated at the end of February aiming to re-raise ACE2 levels without risking increased infection rates. Here, soluble human recombinant ACE2 (rhACE2) infusions were planned in a COVID-19 patient cohort consisting of 24 participants [<xref rid="bb0380" ref-type="bibr">76</xref>]. The conceptual idea is that the non-membrane-bound receptor functions as a trap for viral particles by intercepting SARS-CoV-2, thereby preventing binding to cell surface-located ACE2 and the subsequent infection. Whether this proposed mode of action is only effective in the early phase of infection remains an open question to date. It is generally conceivable that every drug or clinical intervention leading to a decreased viral load might result in an improved outcome combined with reduced long-term complications. However, for non-declared reasons, the promising pilot study has been recently withdrawn as indicated at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" id="ir0005">www.clinicaltrials.gov</ext-link> (NCT number: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04287686" id="ir0010">NCT04287686</ext-link>) [<xref rid="bb0380" ref-type="bibr">76</xref>]. Nevertheless, the pharmaceutical company APEIRON Biologics AG announced a large phase II clinical study a few days ago. They plan to treat 200 COVID-19 patients in Austria, Germany and Denmark with APN01, synonymous for rhACE2 [<xref rid="bb0385" ref-type="bibr">77</xref>]. Importantly, preclinical models reinforce the potential benefit of this treatment. Monteil et al. demonstrated that SARS-CoV-2 infection of engineered human organoids, more precisely blood vessel and kidney organoids, is significantly limited when soluble hrACE2 is applied. In this approach, the group of Penninger specifically investigated the infection-limiting effects at early stages of COVID-19, thus substantiating the previous hypothesis [<xref rid="bb0390" ref-type="bibr">78</xref>]. Altogether, despite the current lack of evidence of efficacy in humans, first studies support the use of rhACE2 to decrease viral load [<xref rid="bb0265" ref-type="bibr">53</xref>,<xref rid="bb0390" ref-type="bibr">78</xref>]. Additional cardio-protective effects of the treatment are also conceivable, although it is questionable whether non-membrane anchored plasma ACE2 can completely fulfil the protease function [<xref rid="bb0315" ref-type="bibr">63</xref>]. To sum up, rhACE2 appears to offer great potential to improve the outcome of COVID-19 patients and minimize adverse chronic damages to the lung, heart and additional organ systems and therefore, the results of the first clinical trials are eagerly anticipated.</p></sec><sec id="s0035"><label>1.6</label><title>Alternative therapeutic approaches</title><p id="p0295">Recently, diverse therapeutic approaches have been considered and several clinical trials have already begun. There is an intriguing variety of proposed pharmacological interventions, which arose from intensive research, the collaboration of many working groups and scientific journals around the globe. There are many possible targets in addition to ACE2, thus combined therapies may be possible and probably even more potent. Here, we highlight some of these therapeutic strategies, which have a special focus on adjuvant therapies to prevent cardiac injury. As mentioned above, high plasmin/plasminogen levels are often abundant in distinct comorbidities, and can therefore serve as a predictive biomarker for risk assessment [<xref rid="bb0300" ref-type="bibr">60</xref>]. It has already been demonstrated in vitro that specific protease inhibitors impair viral entry and based on these results [<xref rid="bb0210" ref-type="bibr">42</xref>], first protease inhibitors are administered in COVID-19 patients in China [<xref rid="bb0395" ref-type="bibr">79</xref>,<xref rid="bb0400" ref-type="bibr">80</xref>]. In this context, the study of Hoffmann et al. revealed that the protease TMPRSS2 is critically involved in SARS-CoV-2 cell entry, so that specific inhibitors or antibodies might have a beneficial effect [<xref rid="bb0235" ref-type="bibr">47</xref>]. Antiviral activity has also been shown for Remdesivir, an inhibitor of the viral RNA polymerase, currently used in the clinics. While compassionate use of this nucleotide analogue improved the outcome in 36 out of 53 COVID-19 patients, placebo-controlled and randomized trials are required to assess the therapeutic efficacy [<xref rid="bb0405" ref-type="bibr">81</xref>]. Indeed, such studies further testing Remdesivir but also several other therapeutic candidates are currently ongoing. <xref rid="t0005" ref-type="table">Table 1</xref>
provides a comprehensive overview of potential COVID-19 therapeutics including their mode of action and their implication for the cardiovascular system.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Potential COVID-19 therapeutics currently under clinical investigation.</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Therapeutic</th><th>Mechanism</th><th>Initial usage</th><th>Cardiac implementation</th></tr></thead><tbody><tr><td colspan="4">Inhibition of the viral cell entry and virus spreading</td></tr><tr><td>Camostat mesylate</td><td><list list-type="simple" id="l0005"><list-item id="li0005"><label>1.</label><p id="p0005">Inhibitor of serine proteases, especially transmembrane protease serine subtype 2 (TMPRSS2),</p></list-item><list-item id="li0010"><label>2.</label><p id="p0010">Protease important for SARS-CoV2 S-protein cleavage for viral membrane fusion.</p></list-item></list></td><td>Therapeutic against pancreatitis<break/>Inhibition of pancreatic fibrosis</td><td><list list-type="simple" id="l0010"><list-item id="li0015"><label>&#x02022;</label><p id="p0015">Additional function: Inhibition of monocyte activation and reduced TNF&#x003b1;-production,</p></list-item><list-item id="li0020"><label>&#x02022;</label><p id="p0020">Reduction of detrimental proinflammatory mechanisms in the heart.</p></list-item></list></td></tr><tr><td>Antiproteases (anti-plasmin)</td><td><list list-type="simple" id="l0015"><list-item id="li0025"><label>1.</label><p id="p0025">Inhibition of endogenous proteases responsible for SARS-CoV2 S-protein cleavage into S1- and S2-subunit (TMPRSS2, Cathepsin B/L, <bold>plasmin</bold>)</p></list-item><list-item id="li0030"><label>2.</label><p id="p0030">Increased plasmin during SARS-CoV2 leads to increased fibrin degradation products (FDPs), hyperfibrinolysis and reduced platelet conc.</p></list-item></list></td><td/><td><list list-type="simple" id="l0020"><list-item id="li0035"><label>&#x02022;</label><p id="p0035">Disturbed blood coagulation may lead to hemophilia or thrombosis,</p></list-item><list-item id="li0040"><label>&#x02022;</label><p id="p0040">anti-proteases directed against plasmin could reverse those effects</p></list-item><list-item id="li0045"><label>&#x02022;</label><p id="p0045">Plasmin additionally induces hypertension by activation of Na<sup>+</sup>-retention</p></list-item></list></td></tr><tr><td>Chloroquine phosphate<break/>Hydroxychloroquine</td><td><list list-type="simple" id="l0025"><list-item id="li0050"><label>1.</label><p id="p0050">Interference with the pH-dependent endosome-mediated entry of SARS-CoV2 by increasing the pH of acidic vesicles</p></list-item><list-item id="li0055"><label>2.</label><p id="p0055">Interference of the sialic acid biosynthesis pathway via inhibition of quinone reductase 2, which leads to a disturbed glycosylation of viral entry receptor ACE-2</p></list-item><list-item id="li0060"><label>3.</label><p id="p0060">Interference with post-translational modification of viral proteins (proteases)</p></list-item><list-item id="li0065"><label>4.</label><p id="p0065">Inhibition of IFN&#x003b1;- and IL-6 expression (anti-inflammatory effect)</p></list-item></list></td><td>Therapeutic against malaria<break/><break/>Hydroxychloroquine: therapeutic against rheumatoid arthritis</td><td><list list-type="simple" id="l0030"><list-item id="li0070"><label>&#x02022;</label><p id="p0070">Treatment with chloroquine/hydroxychloroquine leads to a drug-induced QT-interval prolongation.</p></list-item><list-item id="li0075"><label>&#x02022;</label><p id="p0075">Consequence: torsades de pointes (TdP) tachycardia and increased risk of arrhythmic</p></list-item><list-item id="li0080"><label>&#x02022;</label><p id="p0080">high-risk especially when combined with azithromycin treatment (s. below)</p></list-item><list-item id="li0085"><label>&#x02022;</label><p id="p0085">thorough QT-monitoring necessary</p></list-item></list></td></tr><tr><td>Umifenovir (Arbidol)</td><td><list list-type="simple" id="l0035"><list-item id="li0090"><label>1.</label><p id="p0090">Membrane fusion inhibitor by interaction with hemagglutinin of influenza A</p></list-item><list-item id="li0095"><label>2.</label><p id="p0095">Exact mechanism for treatment of SARS-CoV2 not elucidated</p></list-item></list></td><td>Therapeutic against influenza A</td><td><list list-type="simple" id="l0040"><list-item id="li0100"><label>&#x02022;</label><p id="p0100">protection against other viral infections with heart tropism like Coxsackie virus B5</p></list-item></list></td></tr><tr><td>Soluble human recombinant ACE2 (hrACE2)</td><td>Neutralization of SARS-CoV2 via competitive binding of hrACE2, decelerated virus entry and spread</td><td/><td><list list-type="simple" id="l0045"><list-item id="li0105"><label>&#x02022;</label><p id="p0105">SARS-CoV2 infection and resulting ACE2-downregulation&#x0202f;=&#x0202f;increased AngII conc. and thereby hypertension and vasoconstriction</p></list-item><list-item id="li0110"><label>&#x02022;</label><p id="p0110">Soluble hrACE2 rescues ACE2 function in lung and heart</p></list-item></list></td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Inhibition of the viral RNA-synthesis</td></tr><tr><td>Remdesivir</td><td>Nucleosid-analogue for the selective inhibition of the viral RdRp</td><td>Therapeutic against Ebola virus</td><td><list list-type="simple" id="l0050"><list-item id="li0115"><label>&#x02022;</label><p id="p0115">Increases lung function and decreases viral load</p></list-item><list-item id="li0120"><label>&#x02022;</label><p id="p0120">Recent studies only show moderate improvement in severe case patients (larger cohorts necessary to evaluate effectivity)</p></list-item></list></td></tr><tr><td>Lopinavir/Ritonavir</td><td>Protease-inhibitor: Most likely inhibits viral 3-chemotrypsine-like protease</td><td>HIV-protease inhibitor</td><td><list list-type="simple" id="l0055"><list-item id="li0125"><label>&#x02022;</label><p id="p0125">Effectivity against SARS-CoV2 questionable</p></list-item><list-item id="li0130"><label>&#x02022;</label><p id="p0130">Side effects: hypertriglyceridemia, hypercholesterinemia, hypertension</p></list-item></list></td></tr><tr><td>Ribavirin</td><td>Nucleosid-analogue for the inhibition of the viral RdRp</td><td>Therapeutic against hepatitis C, etc.</td><td><list list-type="simple" id="l0060"><list-item id="li0135"><label>&#x02022;</label><p id="p0135">Effectivity against SARS-CoV2 questionable</p></list-item></list></td></tr><tr><td>Favipiravir</td><td>Nucleosid-analogue for the selective inhibition of the viral RdRp</td><td>Therapeutic against influenza and ebola virus</td><td><list list-type="simple" id="l0065"><list-item id="li0140"><label>&#x02022;</label><p id="p0140">Decreased fever duration</p></list-item><list-item id="li0145"><label>&#x02022;</label><p id="p0145">Increased clearance of viral particles</p></list-item></list></td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Immunotherapeutic, Immunosuppressive</td></tr><tr><td>Interferons [IFN-&#x003b1;]</td><td>Induction of the expression of antiviral genes and the antiviral immune response</td><td/><td><list list-type="simple" id="l0070"><list-item id="li0150"><label>&#x02022;</label><p id="p0150">Inflammation</p></list-item><list-item id="li0155"><label>&#x02022;</label><p id="p0155">No benefit in mortality during clinical studies</p></list-item></list></td></tr><tr><td>Anakinra</td><td>Immunosuppression by inhibition of IL-1-R</td><td>Attenuation of cytokine storm in CAR-T cell therapy</td><td><list list-type="simple" id="l0075"><list-item id="li0160"><label>&#x02022;</label><p id="p0160">Anti-inflammatory effect in the heart</p></list-item></list></td></tr><tr><td>Toclizumab/Siltuximab</td><td>Immunosuppression by inhibition of IL-6-R (Toclizumab) and IL-6 (Siltuximab)</td><td>Attenuation of cytokine storm in CAR-T cell therapy</td><td><list list-type="simple" id="l0080"><list-item id="li0165"><label>&#x02022;</label><p id="p0165">Anti-inflammatory effect in the heart</p></list-item></list></td></tr><tr><td>other immunothe rapeutics: Azithromycin</td><td>Stimulation of host antiviral response through the induction of interferons and IFN-stimulated genes (ISGs)</td><td>Macrolide antibiotic against bacterial infections (e.g. <italic>P. aeruginosa</italic>)</td><td><list list-type="simple" id="l0085"><list-item id="li0170"><label>&#x02022;</label><p id="p0170">Azithromycin leads to a drug-induced QT-interval prolongation via inhibition of iKr</p></list-item><list-item id="li0175"><label>&#x02022;</label><p id="p0175">Consequence: torsades de pointes (TdP) tachycardia</p></list-item><list-item id="li0180"><label>&#x02022;</label><p id="p0180">Increased risk of arrhythmic death</p></list-item></list></td></tr><tr><td colspan="4">Anti-hypertension therapeutics and potential SARS-CoV2 vaccines</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td>ACE-inhibitors<break/>AT<sub>1</sub>-antagonists (Losartan)</td><td>Inhibition of ACE-1 leads to:<break/><list list-type="simple" id="l0090"><list-item id="li0185"><label>1.</label><p id="p0185">less angiotensin II</p></list-item><list-item id="li0190"><label>2.</label><p id="p0190">increased levels of ACE-2 (controversial).</p></list-item><list-item id="li0195"><label>3.</label><p id="p0195">ACE-2 product angiotensin 1&#x02013;7 has a vasodilatory effect</p></list-item></list></td><td/><td><list list-type="simple" id="l0095"><list-item id="li0200"><label>&#x02022;</label><p id="p0200">Increased ACE-2 level initially might result in a higher viral uptake</p></list-item><list-item id="li0205"><label>&#x02022;</label><p id="p0205">Withdrawal of ACE-inhibitors might be detrimental, since Ang II might be responsible for acute lung injury</p></list-item><list-item id="li0210"><label>&#x02022;</label><p id="p0210">ACEII possesses cardioprotective effect</p></list-item></list></td></tr><tr><td>monoclonal neutralizing AB</td><td><list list-type="simple" id="l0100"><list-item id="li0215"><label>1.</label><p id="p0215">SARS-CoV2 specific Abs isolated from convalescent patients</p></list-item><list-item id="li0220"><label>2.</label><p id="p0220">Cross-reactivity of mABs from SARS and MERS</p></list-item></list></td><td/><td><list list-type="simple" id="l0105"><list-item id="li0225"><label>&#x02022;</label><p id="p0225">Risk of immunopathogenic liver reaction by antibody-dependent enhancement of the disease</p></list-item></list></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s0040"><label>2</label><title>Conclusion</title><p id="p0300">When the world health organization (WHO) announced COVID-19 as an international emergency at the end of January and declared it a pandemic in March 2020 [<xref rid="bb0410" ref-type="bibr">82</xref>], several efforts were already made to understand the diagnosis and prognosis of this respiratory syndrome. Noteworthy, there are regional differences in COVID-19 severity, which seem to reflect on socio-economic parameters and the readiness of the healthcare systems to cope with such a challenge. Whether COVID-19 has direct or indirect effects to the young or aged cardiovascular system is poorly understood so far because we are only at the beginning of monitoring the COVID-19. This includes specific biomarker discovery to predict patients at very high risk as well as superior imaging tools to monitor cardiac remodeling and inflammation (e.g. MRI). Especially ACE2 abundancy is of high interest in context of SARS-CoV-2 and a potential impact on cardiac tissue; however, insufficient number of cases has been reported so far to draw reliable conclusion and rhACE2 is rather considered a therapeutic strategy to limit viral infection, which will be now investigated in phase-II clinical trials. In addition, clinical association studies in the early, mid and late phase of COVID-19 are urgently needed to discuss standard care, in particular for HF patients who seem to be at highest risk for a severe course of COVID-19.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0305">The authors declare no conflict of interest in relation to this manuscript.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="other" id="rf0005"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19) Situation Report &#x02013; 89</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2" id="ir0015">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2</ext-link></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Gou</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name></person-group><article-title>Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><volume>94</volume><year>2020</year><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">32173574</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features and treatment of COVID-19 patients in northeast Chongqing</article-title><source>J. Med. Virol.</source><year>2020</year></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title><source>JAMA</source><volume>323</volume><issue>11</issue><year>2020</year><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><mixed-citation publication-type="other" id="or0005">COVID-19 Surveillance Group. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf" id="ir0020">https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf</ext-link>.</mixed-citation></ref><ref id="bb0045"><label>9</label><mixed-citation publication-type="other" id="or0010">LEOSS. Lean European Open Survey on SARS-CoV-2 Infected Patients - Statistics. <ext-link ext-link-type="uri" xlink:href="https://leoss.net/statistics/" id="ir0025">https://leoss.net/statistics/</ext-link>.</mixed-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Wang</surname><given-names>X.-G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Benvenuto</surname><given-names>D.</given-names></name><name><surname>Giovanetti</surname><given-names>M.</given-names></name><name><surname>Ciccozzi</surname><given-names>A.</given-names></name><name><surname>Spoto</surname><given-names>S.</given-names></name><name><surname>Angeletti</surname><given-names>S.</given-names></name><name><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><article-title>The 2019-new coronavirus epidemic: evidence for virus evolution</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">31994738</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.-P.</given-names></name></person-group><article-title>Viral Metagenomics revealed Sendai virus and coronavirus infection of Malayan pangolins (Manis javanica)</article-title><source>Viruses</source><volume>11</volume><year>2019</year></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="other" id="rf0055"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><article-title>Q&#x00026;A on coronaviruses (COVID-19): How long does it take after exposure to COVID-19 to develop symptoms?</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses" id="ir0030">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses</ext-link><year>2020</year></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="other" id="rf0060"><person-group person-group-type="author"><name><surname>Streeck</surname><given-names>H.</given-names></name><name><surname>Hartmann</surname><given-names>G.</given-names></name><name><surname>Exner</surname><given-names>M.</given-names></name><name><surname>Schmid</surname><given-names>M.</given-names></name></person-group><article-title>Vorl&#x000e4;ufiges Ergebnis und Schlussfolgerungen der COVID-19 Case-ClusterStudy (Gemeinde Gangelt)</article-title><ext-link ext-link-type="uri" xlink:href="https://www.land.nrw/sites/default/files/asset/document/zwischenergebnis_covid19_case_study_gangelt_0.pdf" id="ir0035">https://www.land.nrw/sites/default/files/asset/document/zwischenergebnis_covid19_case_study_gangelt_0.pdf</ext-link></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="other" id="rf0065"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19) - Symptoms of Coronavirus</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fabout%2Fsymptoms.html" id="ir0040">https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fabout%2Fsymptoms.html</ext-link></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.-S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>Y.-R.</given-names></name><name><surname>Ye</surname><given-names>L.-L.</given-names></name><name><surname>Peng</surname><given-names>W.-B.</given-names></name><name><surname>Wang</surname><given-names>Z.-H.</given-names></name></person-group><article-title>Clinical characteristics of SARS-CoV-2 infected pneumonia with Diarrhea</article-title><source>SSRN Journal</source><year>2020</year></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Centers for Disease Control and Prevention</surname></name></person-group><source>Coronavirus Disease</source><volume>COVID-19</volume><year>2019</year><fpage>20.03.20</fpage><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html" id="ir0045">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html</ext-link></element-citation></ref><ref id="bb0090"><label>18</label><mixed-citation publication-type="other" id="or0015">World Health Organization (WHO). Q&#x00026;A: Similarities and differences &#x02013; COVID-19 and influenza. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza" id="ir0050">https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza</ext-link>.</mixed-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>M.</given-names></name><name><surname>Heywood</surname><given-names>A.E.</given-names></name><name><surname>Mahimbo</surname><given-names>A.</given-names></name><name><surname>Rahman</surname><given-names>B.</given-names></name><name><surname>Newall</surname><given-names>A.T.</given-names></name><name><surname>Macintyre</surname><given-names>C.R.</given-names></name></person-group><article-title>Acute myocardial infarction and influenza: a meta-analysis of case-control studies</article-title><source>Heart</source><volume>101</volume><year>2015</year><fpage>1738</fpage><lpage>1747</lpage><pub-id pub-id-type="pmid">26310262</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="book" id="rf0085"><person-group person-group-type="author"><name><surname>European Society of Anesthesiology</surname></name></person-group><chapter-title>Analysis of the number growth of ICU patients with Covid-19 in Italy and Lombardy</chapter-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.esahq.org/esa-news/analysis-of-the-number-growth-of-icu-patients-with-covid-19-in-italy-and-lombardy/" id="ir0055">https://www.esahq.org/esa-news/analysis-of-the-number-growth-of-icu-patients-with-covid-19-in-italy-and-lombardy/</ext-link></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study</article-title><source>Radiology</source><volume>200843</volume><year>2020</year></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Dreher</surname><given-names>M.</given-names></name><name><surname>Kersten</surname><given-names>A.</given-names></name><name><surname>Bickenbach</surname><given-names>J.</given-names></name><name><surname>Balfanz</surname><given-names>P.</given-names></name><name><surname>Hartmann</surname><given-names>B.</given-names></name><name><surname>Cornelissen</surname><given-names>C.</given-names></name></person-group><article-title>Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS</article-title><source>Dtsch. Arztebl. Int.</source><volume>2020</volume><year>2020</year><fpage>271</fpage><lpage>278</lpage></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>T.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name></person-group><article-title>Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)</article-title><source>JAMA Cardiol.</source><year>2020</year></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name></person-group><article-title>Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China</article-title><source>JAMA Cardiol</source><year>2020</year></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name></person-group><article-title>An acute respiratory infection runs into the Most common noncommunicable epidemic-COVID-19 and cardiovascular diseases</article-title><source>JAMA Cardiol.</source><year>2020</year></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="book" id="rf0115"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><chapter-title>The Potential Role of IL-6 in Monitoring Severe Case of Coronavirus Disease 2019</chapter-title><year>2020</year></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="other" id="rf0120"><person-group person-group-type="author"><name><surname>&#x000c4;rzteblatt</surname></name></person-group><article-title>Intensivmediziner ver&#x000f6;ffentlichen Empfehlungen zur Therapie von COVID-19-Patienten</article-title><ext-link ext-link-type="uri" xlink:href="https://www.aerzteblatt.de/nachrichten/111046/Intensivmediziner-veroeffentlichen-Empfehlungen-zur-Therapie-von-COVID-19-Patienten" id="ir0060">https://www.aerzteblatt.de/nachrichten/111046/Intensivmediziner-veroeffentlichen-Empfehlungen-zur-Therapie-von-COVID-19-Patienten</ext-link></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="other" id="rf0125"><person-group person-group-type="author"><name><surname>Robert Koch-Institut</surname></name></person-group><article-title>Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19</article-title><ext-link ext-link-type="uri" xlink:href="https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Stellungnahme-Covid-19_Therapie_Diagnose.pdf?__blob=publicationFile" id="ir0065">https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Stellungnahme-Covid-19_Therapie_Diagnose.pdf?__blob=publicationFile</ext-link></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Inciardi</surname><given-names>R.M.</given-names></name><name><surname>Lupi</surname><given-names>L.</given-names></name><name><surname>Zaccone</surname><given-names>G.</given-names></name><name><surname>Italia</surname><given-names>L.</given-names></name><name><surname>Raffo</surname><given-names>M.</given-names></name><name><surname>Tomasoni</surname><given-names>D.</given-names></name></person-group><article-title>Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)</article-title><source>JAMA Cardiol.</source><year>2020</year></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.-Y.</given-names></name><name><surname>Ma</surname><given-names>Y.-T.</given-names></name><name><surname>Zhang</surname><given-names>J.-Y.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19 and the cardiovascular system</article-title><source>Nat. Rev. Cardiol.</source><volume>17</volume><year>2020</year><fpage>259</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">32139904</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.-J.</given-names></name><name><surname>Ni</surname><given-names>Z.-Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.-H.</given-names></name><name><surname>Ou</surname><given-names>C.-Q.</given-names></name><name><surname>He</surname><given-names>J.-X.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title><source>Intensive Care Med</source><volume>46</volume><issue>5</issue><year>2020</year><fpage>846</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">32125452</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="book" id="rf0155"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><chapter-title>Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003</chapter-title><year>2003</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/" id="ir0070">https://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="book" id="rf0160"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><chapter-title>Background and summary of novel coronavirus infection &#x02013; as of 30 November 2012</chapter-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/update_20121130/en/" id="ir0075">https://www.who.int/csr/disease/coronavirus_infections/update_20121130/en/</ext-link></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Alhogbani</surname><given-names>T.</given-names></name></person-group><article-title>Acute myocarditis associated with novel middle east respiratory syndrome coronavirus</article-title><source>Ann Saudi Med</source><volume>36</volume><year>2016</year><fpage>78</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">26922692</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Altered lipid metabolism in recovered SARS patients twelve years after infection</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>9110</fpage><pub-id pub-id-type="pmid">28831119</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Bonow</surname><given-names>R.O.</given-names></name><name><surname>Fonarow</surname><given-names>G.C.</given-names></name><name><surname>O'Gara</surname><given-names>P.T.</given-names></name><name><surname>Yancy</surname><given-names>C.W.</given-names></name></person-group><article-title>Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality</article-title><source>JAMA Cardiol.</source><year>2020</year></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="other" id="rf0180"><person-group person-group-type="author"><name><surname>Cardiology Magazine</surname></name></person-group><article-title>Troponin and BNP Use in COVID-19</article-title><ext-link ext-link-type="uri" xlink:href="https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19" id="ir0080">https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19</ext-link></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Harvell</surname><given-names>B.</given-names></name><name><surname>Henrie</surname><given-names>N.</given-names></name><name><surname>Ernst</surname><given-names>A.A.</given-names></name><name><surname>Weiss</surname><given-names>S.J.</given-names></name><name><surname>Oglesbee</surname><given-names>S.</given-names></name><name><surname>Sarangarm</surname><given-names>D.</given-names></name></person-group><article-title>The meaning of elevated troponin I levels: not always acute coronary syndromes</article-title><source>Am. J. Emerg. Med.</source><volume>34</volume><year>2016</year><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">26508391</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="other" id="rf0190"><person-group person-group-type="author"><name><surname>James</surname><given-names>L.</given-names></name><name><surname>Januzzi</surname><given-names>J.R.</given-names></name></person-group><article-title>Causes of Non ACS Related Troponin Elevations</article-title><ext-link ext-link-type="uri" xlink:href="https://www.acc.org/latest-in-cardiology/articles/2014/07/18/13/16/causes-of-non-acs-related-troponin-elevations" id="ir0085">https://www.acc.org/latest-in-cardiology/articles/2014/07/18/13/16/causes-of-non-acs-related-troponin-elevations</ext-link></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>S.S.</given-names></name><name><surname>Key</surname><given-names>N.S.</given-names></name><name><surname>Greenberg</surname><given-names>C.S.</given-names></name></person-group><article-title>D-dimer antigen: current concepts and future prospects</article-title><source>Blood</source><volume>113</volume><year>2009</year><fpage>2878</fpage><lpage>2887</lpage><pub-id pub-id-type="pmid">19008457</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Fuchs-Buder</surname><given-names>T.</given-names></name><name><surname>de Moerloose</surname><given-names>P.</given-names></name><name><surname>Ricou</surname><given-names>B.</given-names></name><name><surname>Reber</surname><given-names>G.</given-names></name><name><surname>Vifian</surname><given-names>C.</given-names></name><name><surname>Nicod</surname><given-names>L.</given-names></name></person-group><article-title>Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>153</volume><year>1996</year><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">8542111</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Poe</surname><given-names>S.</given-names></name><name><surname>Vandivier-Pletsch</surname><given-names>R.H.</given-names></name><name><surname>Clay</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>H.R.</given-names></name><name><surname>Haynes</surname><given-names>E.</given-names></name><name><surname>Rothenberg</surname><given-names>F.G.</given-names></name></person-group><article-title>Cardiac troponin measurement in the critically ill: potential for guiding clinical management</article-title><source>J. Investig. Med.</source><volume>63</volume><year>2015</year><fpage>905</fpage><lpage>915</lpage></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Rivara</surname><given-names>M.B.</given-names></name><name><surname>Bajwa</surname><given-names>E.K.</given-names></name><name><surname>Januzzi</surname><given-names>J.L.</given-names></name><name><surname>Gong</surname><given-names>M.N.</given-names></name><name><surname>Thompson</surname><given-names>B.T.</given-names></name><name><surname>Christiani</surname><given-names>D.C.</given-names></name></person-group><article-title>Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e40515</object-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hao</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Status of hypertension in China: results from the China hypertension survey, 2012-2015</article-title><source>Circulation</source><volume>137</volume><year>2018</year><fpage>2344</fpage><lpage>2356</lpage><pub-id pub-id-type="pmid">29449338</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>M.K.</given-names></name><name><surname>Atkins</surname><given-names>C.E.</given-names></name><name><surname>Pitt</surname><given-names>B.</given-names></name></person-group><article-title>The renin-angiotensin-aldosterone system and its suppression</article-title><source>J. Vet. Intern. Med.</source><volume>33</volume><year>2019</year><fpage>363</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">30806496</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Ghazi</surname><given-names>L.</given-names></name><name><surname>Drawz</surname><given-names>P.</given-names></name></person-group><article-title>Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy</article-title><source>F1000Res</source><volume>6</volume><year>2017</year></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Iravanian</surname><given-names>S.</given-names></name><name><surname>Dudley</surname><given-names>S.C.</given-names></name></person-group><article-title>The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias</article-title><source>Heart Rhythm.</source><volume>5</volume><year>2008</year><fpage>S12</fpage><lpage>S17</lpage><pub-id pub-id-type="pmid">18456194</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>C.A.</given-names></name><name><surname>Orias</surname><given-names>M.</given-names></name><name><surname>Weir</surname><given-names>M.R.</given-names></name></person-group><article-title>Novel RAAS agonists and antagonists: clinical applications and controversies</article-title><source>Nat Rev Endocrinol</source><volume>11</volume><year>2015</year><fpage>242</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">25666495</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Keidar</surname><given-names>S.</given-names></name><name><surname>Kaplan</surname><given-names>M.</given-names></name><name><surname>Gamliel-Lazarovich</surname><given-names>A.</given-names></name></person-group><article-title>ACE2 of the heart: from angiotensin I to angiotensin (1-7)</article-title><source>Cardiovasc. Res.</source><volume>73</volume><year>2007</year><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">17049503</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>R.A.S.</given-names></name><name><surname>Sampaio</surname><given-names>W.O.</given-names></name><name><surname>Alzamora</surname><given-names>A.C.</given-names></name><name><surname>Motta-Santos</surname><given-names>D.</given-names></name><name><surname>Alenina</surname><given-names>N.</given-names></name><name><surname>Bader</surname><given-names>M.</given-names></name></person-group><article-title>The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)</article-title><source>Physiol. Rev.</source><volume>98</volume><year>2018</year><fpage>505</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">29351514</pub-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.C.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.J.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J. Pathol.</source><volume>203</volume><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>A.J.</given-names></name><name><surname>Hiscox</surname><given-names>J.A.</given-names></name><name><surname>Hooper</surname><given-names>N.M.</given-names></name></person-group><article-title>ACE2: from vasopeptidase to SARS virus receptor</article-title><source>Trends Pharmacol. Sci.</source><volume>25</volume><year>2004</year><fpage>291</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15165741</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.J.</given-names></name></person-group><article-title>Structure analysis of the receptor binding of 2019-nCoV</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>525</volume><year>2020</year><fpage>135</fpage><lpage>140</lpage></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Buhl</surname><given-names>K.B.</given-names></name><name><surname>Oxlund</surname><given-names>C.S.</given-names></name><name><surname>Friis</surname><given-names>U.G.</given-names></name><name><surname>Svenningsen</surname><given-names>P.</given-names></name><name><surname>Bistrup</surname><given-names>C.</given-names></name><name><surname>Jacobsen</surname><given-names>I.A.</given-names></name></person-group><article-title>Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro</article-title><source>J. Hypertens.</source><volume>32</volume><year>2014</year><fpage>1672</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">24805959</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Svenningsen</surname><given-names>P.</given-names></name><name><surname>Hinrichs</surname><given-names>G.R.</given-names></name><name><surname>Zachar</surname><given-names>R.</given-names></name><name><surname>Ydegaard</surname><given-names>R.</given-names></name><name><surname>Jensen</surname><given-names>B.L.</given-names></name></person-group><article-title>Physiology and pathophysiology of the plasminogen system in the kidney</article-title><source>Pflugers Arch.</source><volume>469</volume><year>2017</year><fpage>1415</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">28656379</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Sharma</surname><given-names>N.M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Pliquett</surname><given-names>R.U.</given-names></name><name><surname>Patel</surname><given-names>K.P.</given-names></name></person-group><article-title>Urinary Proteolytic activation of renal epithelial Na+ channels in chronic heart failure</article-title><source>Hypertension</source><volume>67</volume><year>2016</year><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">26628676</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H.-L.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Matalon</surname><given-names>S.</given-names></name><name><surname>Matthay</surname><given-names>M.A.</given-names></name></person-group><article-title>Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility</article-title><source>Physiol. Rev.</source><volume>100</volume><year>2020</year><fpage>1065</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">32216698</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="book" id="rf0290"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>F.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name></person-group><chapter-title>Clinical Characteristics of 82 Death Cases with COVID-19</chapter-title><year>2020</year></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Gheblawi</surname><given-names>M.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name></person-group><article-title>Angiotensin converting enzyme 2: a double-edged sword</article-title><source>Circulation</source><year>2020</year><comment>(epub ahead of print)</comment></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>D.W.</given-names></name><name><surname>Yarski</surname><given-names>M.</given-names></name><name><surname>Warner</surname><given-names>F.J.</given-names></name><name><surname>Thornhill</surname><given-names>P.</given-names></name><name><surname>Parkin</surname><given-names>E.T.</given-names></name><name><surname>Smith</surname><given-names>A.I.</given-names></name></person-group><article-title>Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)</article-title><source>J. Biol. Chem.</source><volume>280</volume><year>2005</year><fpage>30113</fpage><lpage>30119</lpage><pub-id pub-id-type="pmid">15983030</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Kanzaki</surname><given-names>H.</given-names></name><name><surname>Shinohara</surname><given-names>F.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Wada</surname><given-names>S.</given-names></name><name><surname>Miyamoto</surname><given-names>Y.</given-names></name><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name></person-group><article-title>A-Disintegrin and metalloproteinase (ADAM) 17 enzymatically degrades interferon-gamma</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>32259</fpage><pub-id pub-id-type="pmid">27573075</pub-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name><surname>de Lang</surname><given-names>A.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells</article-title><source>Virology</source><volume>353</volume><year>2006</year><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">16860835</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="book" id="rf0315"><person-group person-group-type="author"><name><surname>Schatzmann Peron</surname><given-names>J.P.</given-names></name><name><surname>Nakaya</surname><given-names>H.</given-names></name></person-group><chapter-title>Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding and Antibody-Dependent Enhancement (ADE)</chapter-title><year>2020</year></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>C.M.</given-names></name><name><surname>Jessup</surname><given-names>J.</given-names></name><name><surname>Chappell</surname><given-names>M.C.</given-names></name><name><surname>Averill</surname><given-names>D.B.</given-names></name><name><surname>Brosnihan</surname><given-names>K.B.</given-names></name><name><surname>Tallant</surname><given-names>E.A.</given-names></name></person-group><article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title><source>Circulation</source><volume>111</volume><year>2005</year><fpage>2605</fpage><lpage>2610</lpage><pub-id pub-id-type="pmid">15897343</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name><surname>Ishiyama</surname><given-names>Y.</given-names></name><name><surname>Gallagher</surname><given-names>P.E.</given-names></name><name><surname>Averill</surname><given-names>D.B.</given-names></name><name><surname>Tallant</surname><given-names>E.A.</given-names></name><name><surname>Brosnihan</surname><given-names>K.B.</given-names></name><name><surname>Ferrario</surname><given-names>C.M.</given-names></name></person-group><article-title>Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors</article-title><source>Hypertension</source><volume>43</volume><year>2004</year><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">15007027</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name><surname>Karram</surname><given-names>T.</given-names></name><name><surname>Abbasi</surname><given-names>A.</given-names></name><name><surname>Keidar</surname><given-names>S.</given-names></name><name><surname>Golomb</surname><given-names>E.</given-names></name><name><surname>Hochberg</surname><given-names>I.</given-names></name><name><surname>Winaver</surname><given-names>J.</given-names></name></person-group><article-title>Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><volume>289</volume><year>2005</year><fpage>H1351</fpage><lpage>H1358</lpage><pub-id pub-id-type="pmid">15894569</pub-id></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>J. Am. Heart Assoc.</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">e016219</object-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="other" id="rf0340"><person-group person-group-type="author"><name><surname>de Simone</surname><given-names>G.</given-names></name></person-group><article-title>Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers</article-title><ext-link ext-link-type="uri" xlink:href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang" id="ir0090">https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</ext-link></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Lei</surname><given-names>F.</given-names></name><name><surname>Qin</surname><given-names>J.-J.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name></person-group><article-title>Association of Inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19</article-title><source>Circ. Res.</source><year>2020</year><comment>(epub aheah of print)</comment></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name><surname>Hemnes</surname><given-names>A.R.</given-names></name><name><surname>Rathinasabapathy</surname><given-names>A.</given-names></name><name><surname>Austin</surname><given-names>E.A.</given-names></name><name><surname>Brittain</surname><given-names>E.L.</given-names></name><name><surname>Carrier</surname><given-names>E.J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</article-title><source>Eur. Respir. J.</source><volume>51</volume><year>2018</year></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="journal" id="rf0355"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Benthin</surname><given-names>C.</given-names></name><name><surname>Zeno</surname><given-names>B.</given-names></name><name><surname>Albertson</surname><given-names>T.E.</given-names></name><name><surname>Boyd</surname><given-names>J.</given-names></name><name><surname>Christie</surname><given-names>J.D.</given-names></name></person-group><article-title>A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome</article-title><source>Crit. Care</source><volume>21</volume><year>2017</year><fpage>234</fpage><pub-id pub-id-type="pmid">28877748</pub-id></element-citation></ref><ref id="bb0375"><label>75</label><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections</article-title><source>Nat. Commun.</source><volume>5</volume><year>2014</year><fpage>3594</fpage><pub-id pub-id-type="pmid">24800825</pub-id></element-citation></ref><ref id="bb0380"><label>76</label><element-citation publication-type="other" id="rf0365"><person-group person-group-type="author"><name><surname>ClinicalTrial.gov</surname></name></person-group><article-title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04287686?cond=COVID-19&#x00026;draw=2" id="ir0095">https://clinicaltrials.gov/ct2/show/NCT04287686?cond=COVID-19&#x00026;draw=2</ext-link></element-citation></ref><ref id="bb0385"><label>77</label><element-citation publication-type="other" id="rf0370"><person-group person-group-type="author"><name><surname>APEIRON Biologics AG</surname></name></person-group><article-title>APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19</article-title><ext-link ext-link-type="uri" xlink:href="https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf" id="ir0100">https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf</ext-link></element-citation></ref><ref id="bb0390"><label>78</label><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Prado</surname><given-names>P.</given-names></name><name><surname>Hagelkr&#x000fc;ys</surname><given-names>A.</given-names></name><name><surname>Wimmer</surname><given-names>R.A.</given-names></name><name><surname>Stahl</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2</article-title><source>Cell</source><year>2020</year><comment>(S0092-8674(20)30399, epub ahead of print)</comment></element-citation></ref><ref id="bb0395"><label>79</label><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>S.G.V.</given-names></name><name><surname>Santos</surname><given-names>W.C.</given-names></name></person-group><article-title>Clinical trials on drug repositioning for COVID-19 treatment</article-title><source>Rev. Panam. Salud Publica</source><volume>44</volume><year>2020</year><object-id pub-id-type="publisher-id">e40</object-id></element-citation></ref><ref id="bb0400"><label>80</label><element-citation publication-type="book" id="rf0385"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><chapter-title>First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients</chapter-title><year>2020</year></element-citation></ref><ref id="bb0405"><label>81</label><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>J.</given-names></name><name><surname>Ohmagari</surname><given-names>N.</given-names></name><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Diaz</surname><given-names>G.</given-names></name><name><surname>Asperges</surname><given-names>E.</given-names></name><name><surname>Castagna</surname><given-names>A.</given-names></name></person-group><article-title>Compassionate use of Remdesivir for patients with severe Covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><comment>(epub ahead of print)</comment></element-citation></ref><ref id="bb0410"><label>82</label><element-citation publication-type="book" id="rf0395"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><chapter-title>WHO Director-General's opening remarks at the media briefing on COVID-19</chapter-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020" id="ir0105">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgment</title><p>We acknowledge Dr. Jan Fiedler for fruitful discussions and proofreading of this review. This work was supported by the REBIRTH Center for Translational Regenerative Medicine of <funding-source id="gts0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100005624</institution-id><institution>Hannover Medical School</institution></institution-wrap></funding-source> and by the <funding-source id="gts0010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source>, DFG (KFO311 to TT and TRR267 to CB and TT).</p></ack></back></article>